{"analyses":[{"ciNumSides":"TWO_SIDED","ciPctValue":"95","groupDescription":"Chi-square test of proportions in all patients to compare the proportion of responders (complete response \\[CR\\]+ very good partial response \\[VGPR\\]) at the end of induction therapy in this study to an analogous cohort of responders in A3973.","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0034","paramType":"Chi-squared test statistic","paramValue":"8.5751","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.47","upperLimit":"0.61","value":"0.54"},{"groupId":"OG001","lowerLimit":"0.41","upperLimit":"0.56","value":"0.48"},{"groupId":"OG002","lowerLimit":"0.29","upperLimit":"0.41","value":"0.35"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"176"},{"groupId":"OG002","value":"233"}],"units":"Participants"}],"description":"Per the International Response Criteria: measurable tumor defined as product of longest x widest perpendicular diameter. Elevated catecholamine levels, tumor cell invasion of bone marrow also considered measurable tumor. Complete Response (CR)-no evidence of primary tumor or metastases. Very Good Partial Response (VGPR)-\\>90% reduction of primary tumor; no metastases; no new bone lesions, all pre-existing lesions improved. Partial Response (PR)-50-90% reduction of primary tumor; \\>50% reduction in measurable sites of metastases; 0-1 bone marrow samples with tumor; number of positive bone sites decreased by \\>50%. Mixed Response (MR)-\\>50% reduction of any measurable lesion (primary or metastases) with \\<50% reduction in other sites; no new lesions; \\<25% increase in any existing lesion. No Response (NR)-no new lesions; \\<50% reduction but \\<25% increase in any existing legions. Progressive Disease (PD)-any new/increased measurable lesion by \\>25%; previous negative marrow positive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Induction therapy + single myeloablative consolidation","id":"OG000","title":"Single HST (CEM)"},{"description":"Induction therapy + tandem myeloablative consolidation","id":"OG001","title":"Tandem HST (CEM), Randomly Assigned"},{"description":"Patients that either failed during Induction therapy or refused randomization","id":"OG002","title":"Not Assigned"}],"paramType":"NUMBER","populationDescription":"Eligible patients evaluated for response at the end of induction therapy.","reportingStatus":"POSTED","timeFrame":"Study enrollment to the end of induction therapy","title":"Response After Induction Therapy","type":"PRIMARY","unitOfMeasure":"Proportion participants that responded"}